CJC-1295 vs Ipamorelin

Human data from non-randomized studies: cohorts, case series, case reports.

Preclinical evidence from animal models only — not yet shown in humans.

CJC-1295 starts from GHRH(1-29) — the same sequence behind sermorelin — then bolts on Drug Affinity Complex (DAC) technology that covalently latches the peptide onto circulating albumin. That albumin tether is the whole trick: where sermorelin clears in minutes, CJC-1295 with DAC keeps stimulating GH for six to eight days off a single injection. It activates pituitary GHRH receptors and drives pulsatile GH the physiological way. In practice that means dosing once or twice a week instead of daily — the feature that made it a biohacking favorite. One source of confusion worth flagging: a version without the DAC modification (CJC-1295 without DAC, also called "Modified GRF 1-29") is short-acting, much closer to sermorelin.

Ipamorelin is a synthetic pentapeptide ghrelin mimetic that binds the growth hormone secretagogue receptor (GHSR-1a) and tells the pituitary to release GH. Selectivity is its calling card. Where GHRP-2 and GHRP-6 drag cortisol and ACTH up alongside GH, ipamorelin — in animal studies — lifts GH without significantly moving ACTH or cortisol beyond what GHRH itself does. It also barely touches appetite compared to MK-677, a difference that comes down to how it sits on the receptor. In animal work it usually shares the syringe with a GHRH analog like CJC-1295, the idea being that hitting the GHRH receptor and the GHSR at once amplifies the GH pulse more than either alone.

GH / IGF-1 support, Body composition

GH / IGF-1 support, Body composition

Sold "for research use only" — not approved for human consumption.

Sold "for research use only" — not approved for human consumption.